(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Self-sacrificing ants highlight the unity of their colony, say researchers - 2Embracing Practical Living and Ecological Protection
- 3First Alert: Light snow through this evening
- 4Falcon 9 rocket launches Starlink satellites before making 550th SpaceX landing (video)
- 5Mating injuries may lead scientists to identify dinosaurs’ sex
- Deadly heat worldwide prompts $300 million for climate health research at COP30
- 10 Demonstrated Systems to Develop Your Internet based Business
- Boats escort freed whale away from shallow waters off German coast
- Very good quality Greens All over The Planet
- Which Exhibition hall Do You Suggest? Vote
- Strengthening through Wellness: Individual Preparation Achievement
- Mexico says a third of 130,000 missing people might be alive, fueling criticism from families
- Vote In favor of Your Favored Treat
- The 15 Most Motivating TED Discusses All Time
